Cargando…

The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARM‐CHF randomized controlled trial

AIMS: Patients with heart failure (HF) have impaired quality of life (QoL). The randomized controlled trial PHARM‐CHF investigated whether an interdisciplinary intervention consisting of regular contacts with the community pharmacy and weekly dosing aids improves medication adherence in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Schulz, Martin, Griese‐Mammen, Nina, Schumacher, Pia M., Anker, Stefan D., Koehler, Friedrich, Ruckes, Christian, Rettig‐Ewen, Volker, Wachter, Rolf, Trenk, Dietmar, Böhm, Michael, Laufs, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754956/
https://www.ncbi.nlm.nih.gov/pubmed/32700409
http://dx.doi.org/10.1002/ehf2.12904
_version_ 1783626281273786368
author Schulz, Martin
Griese‐Mammen, Nina
Schumacher, Pia M.
Anker, Stefan D.
Koehler, Friedrich
Ruckes, Christian
Rettig‐Ewen, Volker
Wachter, Rolf
Trenk, Dietmar
Böhm, Michael
Laufs, Ulrich
author_facet Schulz, Martin
Griese‐Mammen, Nina
Schumacher, Pia M.
Anker, Stefan D.
Koehler, Friedrich
Ruckes, Christian
Rettig‐Ewen, Volker
Wachter, Rolf
Trenk, Dietmar
Böhm, Michael
Laufs, Ulrich
author_sort Schulz, Martin
collection PubMed
description AIMS: Patients with heart failure (HF) have impaired quality of life (QoL). The randomized controlled trial PHARM‐CHF investigated whether an interdisciplinary intervention consisting of regular contacts with the community pharmacy and weekly dosing aids improves medication adherence in patients with HF. It is unknown how an intervention involving frequent structured pharmacy visits affects QoL. Our aim was to explore adherence to the intervention and effects on QoL. METHODS AND RESULTS: Among 237 patients, n = 110 were randomized to pharmacy care and n = 127 to usual care. The pharmacy care group received a medication review followed by (bi‐)weekly dose dispensing and counselling. The median follow‐up was 2.0 years [inter‐quartile range (IQR) 1.2–2.7]. Median interval between pharmacy visits was 8.4 days (IQR 8.0–10.3) and the visits lasted in median 14 min (IQR 10–15). Median adherence to the intervention was 96% (IQR 84–100). QoL at 365 days was predefined as a main secondary and at 730 days as another secondary endpoint in PHARM‐CHF. QoL was measured by the Minnesota Living with Heart Failure Questionnaire; and for 111 patients (n = 47 in the pharmacy care group and n = 64 in the usual care group), data were available at baseline, and after 365 and 730 days (mean age 74 years; 41% female). Improvement in QoL was numerically higher in the pharmacy care group after 365 days and was significantly better after 730 days (difference in total scores −7.7 points [−14.5 to −1.0]; P = 0.026) compared to the usual care group. In all subgroups examined, this treatment effect was preserved. Improvements in the physical and emotional dimensions were numerically higher in the pharmacy care group after 365 days and were significantly better after 730 days: −4.0 points [−6.9 to −1.2]; P = 0.006, and −1.9 points [−3.7 to −0.1]; P = 0.039, respectively. CONCLUSIONS: A pharmacy‐based interdisciplinary intervention was well received by the patients and suggests clinically important improvements in QoL.
format Online
Article
Text
id pubmed-7754956
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77549562020-12-23 The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARM‐CHF randomized controlled trial Schulz, Martin Griese‐Mammen, Nina Schumacher, Pia M. Anker, Stefan D. Koehler, Friedrich Ruckes, Christian Rettig‐Ewen, Volker Wachter, Rolf Trenk, Dietmar Böhm, Michael Laufs, Ulrich ESC Heart Fail Original Research Articles AIMS: Patients with heart failure (HF) have impaired quality of life (QoL). The randomized controlled trial PHARM‐CHF investigated whether an interdisciplinary intervention consisting of regular contacts with the community pharmacy and weekly dosing aids improves medication adherence in patients with HF. It is unknown how an intervention involving frequent structured pharmacy visits affects QoL. Our aim was to explore adherence to the intervention and effects on QoL. METHODS AND RESULTS: Among 237 patients, n = 110 were randomized to pharmacy care and n = 127 to usual care. The pharmacy care group received a medication review followed by (bi‐)weekly dose dispensing and counselling. The median follow‐up was 2.0 years [inter‐quartile range (IQR) 1.2–2.7]. Median interval between pharmacy visits was 8.4 days (IQR 8.0–10.3) and the visits lasted in median 14 min (IQR 10–15). Median adherence to the intervention was 96% (IQR 84–100). QoL at 365 days was predefined as a main secondary and at 730 days as another secondary endpoint in PHARM‐CHF. QoL was measured by the Minnesota Living with Heart Failure Questionnaire; and for 111 patients (n = 47 in the pharmacy care group and n = 64 in the usual care group), data were available at baseline, and after 365 and 730 days (mean age 74 years; 41% female). Improvement in QoL was numerically higher in the pharmacy care group after 365 days and was significantly better after 730 days (difference in total scores −7.7 points [−14.5 to −1.0]; P = 0.026) compared to the usual care group. In all subgroups examined, this treatment effect was preserved. Improvements in the physical and emotional dimensions were numerically higher in the pharmacy care group after 365 days and were significantly better after 730 days: −4.0 points [−6.9 to −1.2]; P = 0.006, and −1.9 points [−3.7 to −0.1]; P = 0.039, respectively. CONCLUSIONS: A pharmacy‐based interdisciplinary intervention was well received by the patients and suggests clinically important improvements in QoL. John Wiley and Sons Inc. 2020-07-23 /pmc/articles/PMC7754956/ /pubmed/32700409 http://dx.doi.org/10.1002/ehf2.12904 Text en © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research Articles
Schulz, Martin
Griese‐Mammen, Nina
Schumacher, Pia M.
Anker, Stefan D.
Koehler, Friedrich
Ruckes, Christian
Rettig‐Ewen, Volker
Wachter, Rolf
Trenk, Dietmar
Böhm, Michael
Laufs, Ulrich
The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARM‐CHF randomized controlled trial
title The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARM‐CHF randomized controlled trial
title_full The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARM‐CHF randomized controlled trial
title_fullStr The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARM‐CHF randomized controlled trial
title_full_unstemmed The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARM‐CHF randomized controlled trial
title_short The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARM‐CHF randomized controlled trial
title_sort impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the pharm‐chf randomized controlled trial
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754956/
https://www.ncbi.nlm.nih.gov/pubmed/32700409
http://dx.doi.org/10.1002/ehf2.12904
work_keys_str_mv AT schulzmartin theimpactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT griesemammennina theimpactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT schumacherpiam theimpactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT ankerstefand theimpactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT koehlerfriedrich theimpactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT ruckeschristian theimpactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT rettigewenvolker theimpactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT wachterrolf theimpactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT trenkdietmar theimpactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT bohmmichael theimpactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT laufsulrich theimpactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT schulzmartin impactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT griesemammennina impactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT schumacherpiam impactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT ankerstefand impactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT koehlerfriedrich impactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT ruckeschristian impactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT rettigewenvolker impactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT wachterrolf impactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT trenkdietmar impactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT bohmmichael impactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial
AT laufsulrich impactofpharmacistphysiciancareonqualityoflifeinelderlyheartfailurepatientsresultsofthepharmchfrandomizedcontrolledtrial